Bausch + Lomb Launches Proposed Financing for Xiidra Acquisition
By Robb M. Stewart
Bausch + Lomb is offering $1.4 billion in debt and is looking to secure an incremental term loan facility to help finance the planned acquisition of a dry-eye drug from Novartis.
The eye-care company said Monday a wholly owned subsidiary has launched an offering of new senior secured notes due 2028 to fund the proposed purchase of Xiidra, Novartis's non-steroid eye drop approved to treat the signs and symptoms of dry eye disease, for $1.75 billion in cash, plus possible milestone payments based on sales and pipeline commercialization.
Bausch + Lomb also is seeking to enter into the term loan facility that could in the form of an incremental amendment to its existing credit agreement or a separate credit agreement. The company said it expects to borrow $500 million of new term B loans under the facility.
The deal for Xiidra was first big move by Chief Executive Brent Saunders since he returned to the helm in March. Bausch + Lomb has said the acquisition, which it expects to close by the end of the year, will be immediately accretive.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
September 11, 2023 07:43 ET (11:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks